Home » EISAI INC. RECEIVES SUMMARY JUDGMENT MOTION DECISIONS IN U.S. LEGAL ACTION OVER ACIPHEX ANDA FILINGS
EISAI INC. RECEIVES SUMMARY JUDGMENT MOTION DECISIONS IN U.S. LEGAL ACTION OVER ACIPHEX ANDA FILINGS
Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Eisai Inc. (Headquarters: New Jersey, Chairman and CEO: Hajime Shimizu) announce that they received court decisions on ANDA-related summary judgment motions for Aciphex (Active Ingredient Name: rabeprazole sodium, Product Name in Japan: Pariet) on October 6, 2006.
PR Newswire (http://sev.prnewswire.com/biotechnology/20061008/NYSU01809102006-1.html)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May